Synta Pharmaceuticals (SNTA) -30% and extending its losses from AH trading yesterday after...

|By:, SA News Editor

Synta Pharmaceuticals (SNTA) -30% and extending its losses from AH trading yesterday after disclosing mixed interim results from a Phase IIb/III trial of its ganetespib treatment for lung cancer. Synta is assessing the drug in combination with docetaxel, a leading chemotherapy.